Bleselumab  (Synonyms: ASKP 1240; Anti-Human CD40 Recombinant Antibody)

Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (K_d:  0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection^[1].

Human IgG4 kappa

Human IgG4 kappa, Isotype Control

Human

CD40^[1]

Bleselumab (0-1 μg/mL, 48 h) dose-depently inhibits PBMCs proliferation induced by soluble CD154^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Bleselumab (0.1-10 mg/kg, i.v.) inhibits Delayed-type hypersensitivity (DTH) reaction in cynomolgus monkeys^[2].
Bleselumab (2 mg/kg, i.v.) prolongs renal allograft survival in Cynomolgus monkeys^[3].
Bleselumab (2 or 5 mg/kg, i.v.) together with Tacrolimus (HY-13756) shows a longer median survival time (MST) than monotherapy^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1453067-91-8

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Harland RC, et al. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study. Am J Transplant. 2020 Jan;20(1):159-171.  [Content Brief]

  [2]. Okimura K, et al. Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects. Am J Transplant. 2014 Jun;14(6):1290-9.  [Content Brief]

  [3]. Song L, et al. Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys. Transplantation. 2014 Aug 15;98(3):267-76.  [Content Brief]